Navigation Links
Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook
Date:11/1/2007

-looking and are based on current expectations. Actual results may differ materially. These statements do not include the potential impact of any equity offerings, new business collaborations, or other transactions that may be closed or entered into after November 1, 2007.

Since Dynavax most recently provided its financial outlook in February 2007, the company has successfully executed key strategic partnerships and secured grants that have provided cash and development funding for its programs. Specifically, these include the commercialization collaboration with Merck for HEPLISAV, the funding commitment from Deerfield for TOLAMBA(TM) and preclinical allergy programs, and a grant from NIH for a universal flu vaccine. As a result, the company has significantly increased its cash position and external funding for its R&D programs. As a result of the exercise of the hepatitis B therapy program option under the SDI collaboration, the company expects to reduce its use of SDI funding during the remainder of 2007.

The Company's consolidated cash, cash equivalents, marketable securities and investments held by SDI, or total cash, is projected to be in the range of $87 to $89 million at the end of 2007, as compared to the range of $38 to $42 million projected in February. This is due primarily to the addition of the collaboration with Merck, the Deerfield funding, and the adjustment in the SDI programs.

Total pro forma operating expenses for 2007 continue to be expected to be in the range of $76 to $84 million. Pro forma operating expenses for R&D programs funded by external sources are projected to be in the range of $38 to 40 million, as compared to the range of $29 to $33 million projected in February.

Dynavax Webcast and Conference Call

Dynavax will webcast its conference call today at 9:00 a.m. ET (6:00 a.m. PT) to discuss the agreement with Merck and 3Q 2007 Financial Results and Updated 2007 Outlook. The live webcast can be accessed by v
'/>"/>

SOURCE Dynavax Technologies Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...r University Medical Center at Dallas and the Bayl...introduce insulin genes into the pancreas//. Ins... sugar) to enter the cells of the body to be used ...ltrasound-targeted micro bubble destruction (UTMD)...
...uota issue between government and striking medicos...ing with their demand of setting up an experts com...riking medicos are also expected to meet Union Hea...r in the day. The resident doctors association of...
...ug Administration authority is under pressure as i...rug as an over-the counter drug//. Andrew von Esc...rged to take an independent, non-biased decision o...d to sell its morning after pill or Plan B without...
...ior doctors of Sir Sunderlal hospital in the Banar...unger strike// for the second consecutive day toda...a for the backward castes in the higher education ...nger strike, the agitating doctors formed human ch...
Other Medicine News:Health News:Bubble Technique on the cards For Treatment of Type I diabetes 2
(Date:10/6/2008)... Annual Scientific Conference -, ORLANDO, Fla., O...rmerly Microbia) today announced presentation of d... the role that cyclic guanosine,monophosphate (cGM...dies,demonstrate that cGMP inhibits intestinal pai...a and desensitizes colonic afferent nerves in a,si...
(Date:10/6/2008)...MICADE Therapy is More Likely to Induce Steroid-...tandard Immunomodulator, Azath...ta presented for the first time,from the Phase 3b ...munomodulators and Biologic Therapy (SONIC) may pr...tients with moderate to severe Crohn,s disease.,Ac...
(Date:10/6/2008)...eristics of Naltrexone SR Associated with ...PHOENIX, Oct. 6 /- Orexigen...eutical company focused on the treatment of,obesit...rs, today presented,data showing the investigation...), successfully achieved key objectives (lowered n...
(Date:10/5/2008)...nd Journal of Medicine reaffirm,well-established e...,HandiHaler(R), RIDGEFIELD, Conn., and NEW YORK, ...rstanding Potential Long-term Impacts on Function ...diHaler(R) (tiotropium bromide,inhalation powder),... 4,years as measured by FEV(1) (p<0.001) versus pl...
Breaking Medicine Technology:Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 2New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 5New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 6New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 7New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 8Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 2Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 3Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 4Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 5Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 2Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 3Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 4Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 5Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 6Argosy publishing launches The Visible Body 13442 1Argosy publishing launches The Visible Body 13442 2Argosy publishing launches The Visible Body 13442 3Sleep Medicine Associates Opens New Doors at Swedish Cherry Hill Campus 13437 1Sleep Medicine Associates Opens New Doors at Swedish Cherry Hill Campus 13437 2Diamonds Retirement Study Finds Companies Ill Prepared to Meet Baby Boomers Health and Wealth Needs 13434 1Diamonds Retirement Study Finds Companies Ill Prepared to Meet Baby Boomers Health and Wealth Needs 13434 2Diamonds Retirement Study Finds Companies Ill Prepared to Meet Baby Boomers Health and Wealth Needs 13434 3Diamonds Retirement Study Finds Companies Ill Prepared to Meet Baby Boomers Health and Wealth Needs 13434 4Diamonds Retirement Study Finds Companies Ill Prepared to Meet Baby Boomers Health and Wealth Needs 13434 5New potential drug target for the treatment of atherosclerosis 13430 1New potential drug target for the treatment of atherosclerosis 13430 2New potential drug target for the treatment of atherosclerosis 13430 3
... -- Genotypically Optimized Dosing Results in Impr... -- , MELBOURNE, Australia, and MENLO PARK, Califo...s (ASX: CXS, NASDAQ: CXSP) announced,today the pre...ydrochloride) phase 1/2a dose-escalation study, de...of Quinamed in heavily,pre-treated patients with a...
... Data From the Companies, Novel Heat Shock Protein...olerability, and Biological,Activity , CAMBRIDGE, ...EWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq...ounced updated interim,results from a Phase I clin... (Hsp90) inhibitor, IPI-504, in patients with rela...
Other Medicine Technology:ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO 2ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO 3ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO 4Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 2Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 3Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 4Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 5Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 6Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 7
...tem will define the state of knee implants. Now, f... requirements and increasing surgical options, whi...ons. The GENESIS II femoral components meet these...tomeet todays surgical demands. Clinical issues su...
Cruciate retaining, posterior stabilized and constrained components.
...tmental total knee prosthesis stems from many year...he-art design and manufacturing technologies have ...l function as well as a favorable pressure distrib... keep wear to a minimum. The inherent design of th...
Offset Liners - Plus 5 mm Neutral
Medicine Products: